Information  X 
Enter a valid email address

Peabody Capital No 2 (41LI)


Tuesday 12 May, 2020

Peabody Capital No 2

Directorate Change

RNS Number : 5284M
Peabody Capital No 2 PLC
12 May 2020


Peabody Capital plc/ Peabody Capital No 2 plc

Directorate change


Peabody has today appointed Eamonn Hughes as Chief Financial Officer after a competitive process.


Eamonn has a wealth of experience, having worked for Berkeley and KPMG, and had been in place as Interim Chief Financial Officer since 3rd February  2020.  He joined Peabody in November  2018  as Finance Director, Development and Regeneration.


Commenting on the change in directorate leadership, Peabody chief executive Brendan Sarsfield said : "Eamonn has been an integral part of the executive team during this period of uncertainty caused by the Covid-19 pandemic, and has quickly built the trust of his colleagues and the board. He is supported by a high performing team, and will ensure that we continue to have robust financial and risk management as we plan for the future. We cannot achieve our objectives without strong financial leadership, and his appointment will help us protect and support our residents, staff and communities going forward."


Eamonn Hughes added : "I am excited to take on the role on a permanent basis. My priority will be to ensure we're in a position to keep investing and meeting the challenges in society and the economy head on. We're committed to improving our existing homes and places, modernising services for residents, building new genuinely affordable homes, and helping others grow and succeed though our community foundation. I look forward to working with partners on these priorities, helping us to make the most impact for people who need us."


For more information, contact: Benjamin Blades, Head of External Affairs, Peabody on  07875020950  or  [email protected]



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t